Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | CCR9 | P51686 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197842 | 0.88 | GRM4 (0.75) | LMNAGAAGRM4SMN1; SMN2RAB9A | |
| SCHEMBL12197845 | 0.86 | MAPT (0.80) | LMNAMAPTGAAGRM4SMN1; SMN2 | |
| SCHEMBL12197843 | 0.84 | MAPT (0.74) | LMNAMAPTGAAGRM4SMN1; SMN2 | |
| SCHEMBL8626109 | 0.82 | CCR9 (0.66) | MAPTGAAGRM4SMN1; SMN2RAB9A | |
| SCHEMBL12197857 | 0.79 | GRM4 (0.78) | LMNAMAPTGAAGRM4SMN1; SMN2 | |
| SCHEMBL12197943 | 0.78 | GRM4 (0.66) | LMNAGAAGRM4SMN1; SMN2RAB9A | |
| SCHEMBL3092361 | 0.78 | SMN1; SMN2 (1.00) | MAPTGAAGRM4SMN1; SMN2RAB9A | |
| SCHEMBL12197850 | 0.78 | GRM4 (0.76) | LMNAGAAGRM4SMN1; SMN2RAB9A | |
| SCHEMBL27179438 | 0.78 | MAPT (1.00) | LMNAMAPTGAAGRM4SMN1; SMN2 | |
| SCHEMBL30926909 | 0.78 | MAPT (1.00) | LMNAMAPTGAAGRM4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110243844-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK SHARP & DOHME CORP. | 2011-10-06 | — | — | US | disclosed |
| US-20110243844-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK SHARP & DOHME CORP. | 2011-10-06 | — | — | US | disclosed |
| WO-2010033350-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK & CO., INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243844-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | GRM4, GRIA4, GRM1 | LMNA 4874/4885MAPT 1712/4885GAA 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.